Prolonged survival following palliative renal tumor embolization by capillary occlusion.
Nine patients with renal cell carcinoma and severe hematuria were palliatively treated with a new type of angioocclusion: the concept of capillary embolization. The so-called occlusion gel Ethibloc was used as embolizing agent. Each patient was followed up until death or for at least 4 years. All patients had a stage T3 or T4 tumor, 3 patients had metastases to multiple organs, 3 had lung metastases, and 3 were free of metastatic disease. In all cases, very high volumes (14-40 ml) of the embolizing agent were necessary to achieve total occlusion of the entire arterial compartment. Patients without metastatic disease had a mean survival time of 6 years and 4 months, all of them without signs of malignant disease. Patients with metastases had a mean survival time of 3 years. Compared with the natural history of renal cell carcinoma treated otherwise, this represents a substantial prolongation of survival time. Contrary to other angioocclusive treatment modalities, the concept of capillary occlusion with Ethibloc seems to achieve total tumor destruction.
Kauffmann
G W
GW
Department of Diagnostic Radiology, University of Freiburg, Germany.
Richter
G M
GM
Rohrbach
R
R
Wenz
W
W
D002196:Capillaries; D002292:Carcinoma, Renal Cell / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D003973:Diatrizoate; D004338:Drug Combinations; D004621:Embolization, Therapeutic / Q000379:methods*; D005227:Fatty Acids; D006801:Humans; D007668:Kidney / Q000000981:diagnostic imaging; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D011379:Prognosis; D011409:Propylene Glycols; D011506:Proteins / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed; D015028:Zein
D004338:Drug Combinations; D005227:Fatty Acids; D011409:Propylene Glycols; D011506:Proteins; D003973:Diatrizoate; D015028:Zein; C020481:alcoholic prolamine solution